NDA 218711 · Zhuhai
Beizray
Docetaxel · Intravenous · Microtubule Inhibitor
Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Oct 23, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,918
729 Phase 3, 316 recruiting
FAERS reports
68,067
53,536 serious, 8,967 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with BEIZRAY is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non- small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive BEIZRAY as a single agent at a dose of 100 mg/m 2 [ see Warnings and Precautions ( 5.1 ) ] . Avoid the use of BEIZRAY in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis,...
What it is approved for
From the label in effect Oct 19, 2026.
BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer BEIZRAY in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- BEIZRAY · DOCETAXEL 20MG/ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- BEIZRAY · DOCETAXEL 80MG/4ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Docetaxel" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph NodesPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00003782 · 5,351 participants · Start Mar 1999 · Primary completion Dec 2008
Drug: cyclophosphamide; docetaxel and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 157 sites in all
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerPivotal-lookingCompleted
Women's Cancer Study Group GmbHAcademic, hospital or other
NCT01779206 · 4,936 participants (planned) · Start May 2012 · Primary completion Sep 2019
Drug: Epirubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Munich, Germany; Mönchengladbach, Germany
- Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00093795 · 4,894 participants · Start Oct 2004 · Primary completion Mar 2012
Drug: Cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Stuart, Florida · 12 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT01547741 · 4,242 participants · Start Apr 2012 · Primary completion May 31, 2022
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 915 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- alopecia16,994
- madarosis6,718
- hair texture abnormal5,993
- hair colour changes5,874
- hair disorder5,625
- diarrhoea5,333
- nausea3,877
- emotional distress3,615
- anxiety3,462
- neutropenia3,415
- fatigue3,285
- febrile neutropenia3,101
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 311 |
| 2005 | 420 |
| 2006 | 369 |
| 2007 | 442 |
| 2008 | 633 |
| 2009 | 879 |
| 2010 | 947 |
| 2011 | 1,384 |
| 2012 | 1,780 |
| 2013 | 1,648 |
| 2014 | 1,567 |
| 2015 | 2,012 |
| 2016 | 2,281 |
| 2017 | 4,814 |
| 2018 | 10,853 |
| 2019 | 7,728 |
| 2020 | 5,638 |
| 2021 | 4,532 |
| 2022 | 4,137 |
| 2023 | 4,129 |
| 2024 | 4,611 |
| 2025 | 4,120 |
| 2026 | 2,832 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J, Cortés J, Kim SB, et al. · N Engl J Med 2012 · Comparative Study, Multicenter Study
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J, Reckamp KL, Baas P, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.
Fang W, Li X, Wang Q, et al. · BMJ 2025 · Randomized Controlled Trial, Multicenter Study
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF, de Wit R, Berry WR, et al. · N Engl J Med 2004 · Clinical Trial, Clinical Trial, Phase III
Sponsor: Zhuhai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.